Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant Factor VIIa.

C J Dunn1, C M Spencer

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet.

European journal of hybrid imaging·2022
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Bisphosphonates: a review of their novel anti-inflammatory properties and potential for the treatment of rheumatoid arthritis.

IDrugs : the investigational drugs journal·2008
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Recombinant factor VIIa effectively controls bleeding in hemophilia patients with inhibitors, offering a safe and well-tolerated treatment option. This advanced therapy expedites coagulation without needing factors VIII or IX.

Area of Science:

  • Biotechnology
  • Hematology
  • Pharmacology

Background:

  • Recombinant factor VIIa (rFVIIa) is a biotechnologically produced hemostatic agent.
  • Hemophilia A and B patients with inhibitors to factors VIII or IX present significant treatment challenges.
  • Traditional factor replacement therapy is often ineffective or complicated in these patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant factor VIIa in managing bleeding episodes in hemophilia patients with inhibitors.
  • To assess the hemostatic potential and coagulation time alterations following rFVIIa administration.
  • To explore the feasibility of home treatment programs using self-administered rFVIIa.

Main Methods:

  • Pharmacodynamic studies involving administration of rFVIIa at doses up to 90 microg/kg.

Related Experiment Videos

  • Clinical trials assessing rFVIIa efficacy in controlling joint, muscle, and mucocutaneous bleeding.
  • Evaluation of postoperative hemostasis in patients receiving multiple doses of rFVIIa.
  • Assessment of rFVIIa use in internal or central nervous system (CNS) bleeding.
  • Analysis of home treatment programs involving self-administration or caregiver administration of rFVIIa.

    • Main Results:

    • rFVIIa significantly decreased prothrombin times and activated partial thromboplastin times without altering systemic coagulation activation markers.
    • Effective control of bleeding was observed in patients with hemophilia A or B with inhibitors at doses ranging from 17.5 to 120 microg/kg.
    • Satisfactory hemostasis was achieved postoperatively with multiple rFVIIa doses.
    • Efficacy was noted in managing internal and CNS bleeding in smaller patient cohorts.
    • Home treatment programs demonstrated successful bleeding episode control with self-administration, reducing hospital admissions.

    Conclusions:

    • Recombinant factor VIIa is an effective and well-tolerated therapeutic option for hemophilia patients with inhibitors.
    • The drug facilitates rapid hemostasis and can be safely administered in outpatient and home settings.
    • No thrombotic complications or antibody formation against rFVIIa were reported, indicating a favorable safety profile.